Quarterly Earnings

LegalZoom Stock (LZ): Growth Continues as Margins Improve

LegalZoom's Q2 CY2025 revenue reached $192.5 million, surpassing expectations, with strong cash flow and improved profitability metrics.

nLIGHT Stock (LASR): Q2 Growth and Profitability Outlook

nLIGHT posts a strong Q2 2025 with $61.7M in revenue and 49% growth in Aerospace sales, turning EPS positive and signaling a potential long-term rebound.

SoundHound (SOUN) Soars: Q2 Revenue Jumps 217% Amid Voice AI Boom

SoundHound's Q2 revenue surged 217% year-over-year to $42.7 million, beating forecasts as enterprise demand for voice AI accelerates across restaurants, healthcare, and automotive sectors.

Tutor Perini Stock (TPC): Financial Momentum and Growth Prospects

Tutor Perini crushed Q2 with a 315% EPS jump and record cash flow—setting the stage for more gains as high-margin projects ramp up.

Duolingo Stock (DUOL): AI and Music Learning Propel Performance

Duolingo just crushed Q2 expectations, sending shares soaring up to 20% as it leans hard into AI and dives into gamified music learning.

Cricut Stock (CRCT): Earnings Beat Yet Analyst Caution

Cricut (CRCT) beats Q2 earnings but faces analyst caution.

Champion Homes Stock (SKY): Strong Q1 Earnings Surge

Champion Homes (SKY) shines with Q1 FY26 results, positive growth, and strategic milestones boosting investor confidence.

Flywire Stock (FLYW): Strong Earnings and Growth Potential

Flywire's Q2 2025 revenue grew 27% to $131.9M while EBITDA surged to $16.6M, reflecting strong growth prospects in travel and strategic acquisitions.

Indivior Stock (INDV): Strong Earnings Boost Investor Confidence

Indivior exceeded Q2 2025 expectations, raising full-year forecasts, driven by strong Sublocade demand, boosting stock by ~21%.

CVS Health Stock (CVS): Strong Q2 Performance and Future Outlook

CVS Health showed strong Q2 2025 results, boosting EPS guidance and share price, driven by Aetna and pharmacy growth.

Biogen Stock (BIIB): Strong Q2 Performance Fuels Growth

Biogen's Q2 2025 shows strong growth with new drugs boosting revenue and EPS, despite challenges in legacy MS treatments.

Xylem Stock (XYL): Strong Earnings and Growth Outlook

Xylem reported strong Q2 2025 results, raising full-year guidance amid robust revenue growth.

Interface Stock (TILE): Impressive Q2 Leads to Growth

Interface’s Q2 2025 shows strong growth, with net sales up 8.3% year-over-year and adjusted EPS rising 50% to $0.60, prompting an increase in full-year revenue guidance to $1.37B–$1.39B.

Generac Stock (GNRC): Strong Earnings Boost Confidence

Generac posted strong Q2 earnings with better-than-expected EPS and revenue growth, boosting investor confidence in its stock.

Tilray Stock (TLRY): Q4 Results Weigh on Future Prospects

Tilray's Q4 2025 results show challenges, yet international sales soar 71% as company aims for turnaround.